BioSight
Companies
BioNTech SE logo

BNTX

NASDAQMAINZ, 2M
BioNTech SE
$103.45-0.67%1Y
BNTX · daily close · illustrative · 0 catalysts marked
$80$91$102$112$123Apr '25Aug '25Dec '25Apr '26
1Y high$119.341Y low$83.89range$35.45(42%)past catalysts

Pipeline50

Atezolizumab
Phase 3Extensive Stage Small Cell Lung Cancer
small-molecule
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
Phase 3SARS-CoV-2 Virus
Phase 3Severe Acute Respiratory Syndrome Coronavirus 2
Phase 3COVID-19
small-molecule
BNT162b2 (2025/2026 formulation)
Phase 3COVID-19
Phase 3SARS-COV-2 Infection
small-molecule
BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)
Phase 3COVID-19
Phase 3SARS-COV-2 Infection
small-molecule
BNT162b2 Vaccine
Phase 3COVID-19
Phase 3SARS-COV-2 Infection
small-molecule
BNT323/DB-1303
Phase 3Endometrial Cancer
small-molecule
Carboplatin
Phase 2/3Non-Small Cell Lung Cancer
Phase 2Extensive Stage Small Cell Lung Cancer
Phase 2Small Cell Lung Cancer
Phase 2Locally Advanced Breast Cancer
Phase 2Metastatic Triple Negative Breast Cancer
Phase 2Breast Cancer
Phase 3Breast Cancer
small-molecule
Carboplatin (or cisplatin if carboplatin is not tolerated)
Phase 3Extensive Stage Small Cell Lung Cancer
small-molecule
Docetaxel
Phase 3Endometrial Cancer
Phase 2Non-Small Cell Lung Cancer
small-molecule
Doxorubicin
Phase 3Endometrial Cancer
small-molecule
Eribulin
Phase 2Locally Advanced Breast Cancer
Phase 2Metastatic Triple Negative Breast Cancer
Phase 2Breast Cancer
Phase 3Breast Cancer
small-molecule
Etoposide
Phase 3Extensive Stage Small Cell Lung Cancer
Phase 2Small Cell Lung Cancer
small-molecule
Gemcitabine
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2Locally Advanced Breast Cancer
Phase 2Metastatic Triple Negative Breast Cancer
Phase 2Breast Cancer
Phase 3Breast Cancer
small-molecule
Nab-paclitaxel/Paclitaxel
Phase 3Breast Cancer
small-molecule
Paclitaxel
Phase 3Endometrial Cancer
Phase 2/3Non-Small Cell Lung Cancer
Phase 2Extensive Stage Small Cell Lung Cancer
Phase 2Small Cell Lung Cancer
Phase 2Locally Advanced Breast Cancer
Phase 2Metastatic Triple Negative Breast Cancer
Phase 2Breast Cancer
small-molecule
Pumitamig
Phase 3Extensive Stage Small Cell Lung Cancer
Phase 2Advanced Solid Tumor
Phase 2Non-Small Cell Lung Cancer
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2Recurrent Glioblastoma
Phase 3Breast Cancer
small-molecule
Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
Phase 3SARS-CoV-2 Virus
Phase 3Severe Acute Respiratory Syndrome Coronavirus 2
Phase 3COVID-19
small-molecule
Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose
Phase 3SARS-CoV-2 Virus
Phase 3Severe Acute Respiratory Syndrome Coronavirus 2
Phase 3COVID-19
small-molecule
BNT113
Phase 2/3Unresectable Head and Neck Squamous Cell Carcinoma
Phase 2/3Metastatic Head and Neck Cancer
Phase 2/3Recurrent Head and Neck Cancer
small-molecule
Pembrolizumab
Phase 2Non-Small Cell Lung Cancer
Phase 2/3Unresectable Head and Neck Squamous Cell Carcinoma
Phase 2/3Metastatic Head and Neck Cancer
Phase 2/3Recurrent Head and Neck Cancer
small-molecule
Pemetrexed
Phase 2/3Non-Small Cell Lung Cancer
small-molecule
Bevacizumab
Phase 2Metastatic Colorectal Cancer
Phase 2Recurrent Glioblastoma
small-molecule
BNT164a1
Phase 2Tuberculosis
small-molecule
BNT164b1
Phase 2Tuberculosis
small-molecule
BNT166a
Phase 2Mpox (Monkeypox)
Phase 2Smallpox
Phase 2Orthopoxvirus Infection
small-molecule
BNT314
Phase 2Metastatic Colorectal Cancer
small-molecule
BNT3212
Phase 2Advanced Solid Tumor
small-molecule
BNT3214
Phase 2Advanced Solid Tumor Cancer
small-molecule
BNT323
Phase 2Locally Advanced Breast Cancer
Phase 2Unresectable Breast Carcinoma
Phase 2Breast Cancer
small-molecule
BNT324
Phase 2Advanced Lung Cancer
small-molecule
BNT326
Phase 2Advanced Solid Tumor
Phase 2Non-Small Cell Lung Cancer
small-molecule
BNT327
Phase 2Advanced Lung Cancer
Phase 2Metastatic Colorectal Cancer
Phase 2Locally Advanced Breast Cancer
Phase 2Unresectable Breast Carcinoma
Phase 2Non-Small Cell Lung Cancer
Phase 2Breast Cancer
small-molecule
BNT327 Dose Level 1 (DL1)
Phase 2Extensive Stage Small Cell Lung Cancer
Phase 2Small Cell Lung Cancer
Phase 2Locally Advanced Breast Cancer
Phase 2Metastatic Triple Negative Breast Cancer
Phase 2Breast Cancer
small-molecule
BNT327 Dose Level 1 (DL2)
Phase 2Locally Advanced Breast Cancer
Phase 2Metastatic Triple Negative Breast Cancer
Phase 2Breast Cancer
small-molecule
BNT327 Dose Level 2 (DL2)
Phase 2Extensive Stage Small Cell Lung Cancer
Phase 2Small Cell Lung Cancer
small-molecule
BNT327 Equivalent Q3W Dose
Phase 2Locally Advanced Breast Cancer
Phase 2Metastatic Triple Negative Breast Cancer
Phase 2Breast Cancer
small-molecule
BNT327 Optimized Dose
Phase 2Locally Advanced Breast Cancer
Phase 2Metastatic Triple Negative Breast Cancer
Phase 2Breast Cancer
small-molecule
BNT329
Phase 2Advanced Solid Cancers
small-molecule
CA19-9-targeting monoclonal antibody
Phase 2Advanced Solid Cancers
small-molecule
Itraconazole
Phase 2Advanced Solid Tumor
small-molecule
mFOLFIRINOX
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
small-molecule
Nab-paclitaxel
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
small-molecule
Nab-placlitaxel
Phase 2Locally Advanced Breast Cancer
Phase 2Metastatic Triple Negative Breast Cancer
Phase 2Breast Cancer
small-molecule
Paroxetine
Phase 2Advanced Solid Tumor
small-molecule
RO7198457 intravenous (IV)
Phase 2Colorectal Cancer Stage II
small-molecule
SoC
Phase 2Non-Small Cell Lung Cancer
small-molecule
SoC chemotherapy treatment 1
Phase 2Metastatic Colorectal Cancer
small-molecule
SoC chemotherapy treatment 2
Phase 2Metastatic Colorectal Cancer
small-molecule
Temozolomide
Phase 2Recurrent Glioblastoma
small-molecule
Topotecan
Phase 2Extensive Stage Small Cell Lung Cancer
Phase 2Small Cell Lung Cancer
small-molecule

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar